Systagenix has added another wound marker to its pipeline; Mitochondrial mutations lower in colon cancer cells;

> In an unexpected finding, mitochondrial mutations are lower in colon cancer cells than in healthy cells. Abstract

> Plasma tau levels could lead to a blood test to diagnose Alzheimer's disease. Press release

> U.K.-based wound diagnostic company Systagenix has acquired the assets of O2 Insights, adding a third marker to its wound diagnostics pipeline. Press release

> A p53 mutation can affect breast cancer response to doxorubicin. Press release

> N-terminal pro-brain natriuretic peptide (NT-proBNP) could be used to screen for systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). Abstract

> Interleukin-6 has potential as a biomarker for severe pandemic H1N1 influenza A infection. Paper

> In a German study, a genetic biomarker could tag lung cancer at an early stage. Press release

> A simple blood biomarker test, detecting levels of troponin T, could be used to detect an increased risk of death in the month after non-cardiac surgery. Press release

> Circulating tumor cells provide a blood "snapshot" for cancer drug response in neuroendocrine tumors. Press release | Abstract

> An immune system issue has been tied to a fourfold higher likelihood of death. Press release

And Finally… Biomarker-based diagnostics company Astute Medical has completed a $40.4 million Series C financing. Press release

Suggested Articles

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.